Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:14:17 EST Wed 11 Feb 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Z:ANRO - ALTO NEUROSCIENCE INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ANRO - Z0.114.87·28.000.116.65-0.175-1.0295.74,5573,50716.85  16.85  16.1820.9075  1.60Feb 10Feb 0315 min RT 2¢

Recent Trades - Last 10 of 3507
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-03 08:27U:ANRONews ReleaseAlto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
2026-01-14 07:27U:ANRONews ReleaseAlto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
2026-01-13 08:00U:ANRONews ReleaseAlto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
2025-11-12 07:57U:ANRONews ReleaseAlto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights
2025-11-11 08:55U:ANRONews ReleaseNYSE Content Advisory: Pre-Market Update + Government Shutdown Nears End After 42 Days
2025-10-28 07:34U:ANRONews ReleaseAlto Neuroscience to Participate in Upcoming Investor Conferences
2025-10-20 07:03U:ANRONews ReleaseAlto Neuroscience Announces $50 Million Private Placement Financing
2025-10-20 07:01U:ANRONews ReleaseAlto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting
2025-10-03 07:34U:ANRONews ReleaseAlto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia
2025-09-09 07:09U:ANRONews ReleaseAlto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia
2025-08-18 08:03U:ANRONews ReleaseAlto Neuroscience to Participate in Upcoming Investor Conferences
2025-08-13 16:10U:ANRONews ReleaseAlto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights
2025-08-13 08:03U:ANRONews ReleaseAlto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors
2025-06-30 08:03U:ANRONews ReleaseAlto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression
2025-06-26 07:33U:ANRONews ReleaseAlto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203
2025-06-03 06:03U:ANRONews ReleaseAlto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway
2025-05-29 08:03U:ANRONews ReleaseAlto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder
2025-05-28 08:03U:ANRONews ReleaseAlto Neuroscience to Participate in Upcoming Investor Conferences
2025-05-14 16:10U:ANRONews ReleaseAlto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights